Kornimate/medical-research-clean huggingface dataset:
dietary sodium, oxidative stress, and pulsatile hemodynamics

Conditions: Sodium Excess

Summary: high sodium diets impair vascular function, which may influence the work of the heart. this investigation is designed to determine if this change in vascular function results in a greater workload in the heart and if people who regularly exercise are protected from these effects.

excess dietary sodium is associated with cardiac hypertrophy independent of changes in blood pressure. importantly, increased arterial pulsatile load predicts left ventricular hypertrophy, and thus presents a potential mechanism through which high dietary sodium augments cardiovascular disease risk. while high sodium diets impair vascular function via an increase in oxidative stress, how high sodium influences central pulsatile hemodynamics is not known. this project aims to a) determine how impaired vascular function affects pulsatile hemodynamics and thus influences the work of the heart during periods of high sodium consumption and b) examine whether regular aerobic exercise and/or fitness protects against the deleterious effects of excess sodium.

Eligibility criteria:
inclusion criteria: * healthy individuals (age 21-45) who are either sedentary (1 or less days of exercise per week during past year) or habitually active (4 or more days of aerobic exercise per week for a minimum of 1 year) exclusion criteria: * body mass index \ 35 * systolic blood pressure ≥140 mmhg and/or diastolic blood pressure ≥90 * blood donation within past 8 weeks, * glucose 6 phosphate dehydrogenase (g6pd) deficiency * a history of cancer, diabetes, or any other chronic disease * a history of any heart disease * a history of hormone therapy * use of nicotine products * pregnancy * nursing mothers * participation in regular physical activity greater than 1 day/week- but less than 4 days/week

Keywords: endothelium oxidative stress physical activity ventricular-vascular coupling pulsatile load
a study of minimally invasive proximal gastrectomy versus minimally invasive total gastrectomy for gastric and gastroesophageal junction cancers

Conditions: Gastric Cancer; GastroEsophageal Cancer; Gastroesophageal Junction Adenocarcinoma

Summary: participants will a diagnosis of gastroesophageal junction (gej) adenocarcinoma and will have either a minimally invasive proximal gastrectomy (mipg) or a minimally invasive total gastrectomy (mitg) as part of their routine care. participants with complete a questionnaire 1 month before the surgical procedure and then 1, 3, 6 and 12 months after the surgical procedure.


Eligibility criteria:
inclusion criteria: * able to speak and read english, spanish, japanese or korean * patients with a biopsy-confirmed diagnosis of non-metastatic gastric or gej adenocarcinoma, who are scheduled to undergo mipg or mitg for curative-intention * age ≥ 18 exclusion criteria: * patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract * patients with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent * subjects deemed unable to comply with study and/or follow-up procedures, at investigators' discretion * patients who are pregnant (since are excluded from receiving standard-of-care mipg or mitg)

Keywords: gastric cancer non-metastatic gastric cancer gastroesophageal junction adenocarcinoma gastroesophageal cancer gej adenocarcinoma mipg mitg minimally invasive proximal gastrectomy minimally invasive total gastrectomy 23-324 memorial sloan kettering cancer center
ect vs. esketamine

Conditions: Treatment Resistant Depression; Major Depressive Disorder

Summary: treatment-resistant depression (trd) is a common cause of disability and one of the most common psychiatric disorders worldwide. electroconvulsive therapy (ect) is currently the most effective treatment for trd. recent developments showed esketamine to be a rapid-acting and effective antidepressant drug and it has been hailed as a breakthrough in treating trd. common treatment algorithms for trd list ect as a treatment option, but esketamine has not yet found its exact position in those algorithms. to the investigators' knowledge, a longitudinal, randomized controlled trial comparing the efficacy of ect and intranasal esketamine in trd patients has not been conducted. furthermore, the investigators intend to measure effects of ect and intranasal esketamine on brain connectivity and structure, using functional magnetic resonance imaging (fmri). in this study, inpatients with trd at the university hospital for psychiatry i, medical university innsbruck, will be randomized to ect or intranasal esketamine. short- and medium-term treatment effects on functional and structural connectivity in the brain will be determined using fmri.


Eligibility criteria:
inclusion criteria: 1. dsm-5 diagnosis of major depressive disorder (mdd) without psychotic features (296.22, 296.23, 296.32, 296.33) made through the structured clinical interview for the dsm-v (scid-v). 2. madrs score ≥ 25 3. pharmacologically treatment-resistant depressive episode \[stage ≥ ii, defined by thase \& rush (1997): failure of at least 2 adequate trials of at least 2 distinctly different classes of antidepressants (≥ 4 weeks each)\] (88). 4. age: 18 - 50 years 5. written informed consent exclusion criteria: 1. participation in another interventional clinical trial 2. relative contraindications to ect treatment in accordance with the consensus paper of the austrian society of psychiatry and psychotherapy: 3. patients who meet any exclusion criteria for nasal esketamine treatment as described in the clinical guidelines 4. contraindications to the conduction of mri 5. history of one or more of the following diagnoses (dsm-5): * mdd, single or recurrent episode with psychotic features (296.24; 296.34) * past or current substance dependence (except caffeine, nicotine) (303.x, 304.x, 305.x) * neurodevelopmental disorders (299.x, 307.x, 314.x, 315.x, 319.x) * schizophrenia spectrum and other psychotic disorders (293.x, 295.x, 297.x, 298.x) * neurocognitive disorders (290.x, 292.x, 294.x, 331.x). 6. history of ect (unsuccessful or successful) 7. suicidal tendency requiring admission in a locked ward 8. pregnancy or lactation period 9. lack of anesthetic clearance for any other reason 10. insufficient command of german language.
us eeva™ pregnancy investigational clinical study (us epic)

Conditions: Infertility

Summary: the purpose of this clinical investigation is to gather data to evaluate the impact of using eeva with traditional morphology grading on implantation rates.

the purpose of this clinical investigation is to gather data to evaluate the impact of implantation rates for day 3 embryo transfers using eeva and morphology grading (test group) versus day 3 embryo transfers using morphology grading only (from a concurrent control group).

Eligibility criteria:
inclusion criteria: * women undergoing fresh in vitro fertilization treatment using their own eggs or donor eggs. * ivf cycle attempts ≤ 2. * egg age ≤ 40 years. * planned day 3 embryo transfer. * at least 4 normally fertilized eggs (2pn). * all 2pn embryos must be imaged by eeva. * ejaculated sperm or sperm from the epididymis (fresh or frozen). * willing to comply with study protocol and procedures. * willing to provide written informed consent. exclusion criteria: * planned preimplantation genetic diagnosis or preimplantation genetic screening. * planned "freeze all" cycle (oocytes or embryos). * sperm retrieved from testicular tissue. * abnormal uterine cavity as evaluated by standard methods. * gestational carrier. * endometriosis * hydrosalpinx. * history of cancer. * concurrent participation in another clinical study.

Keywords: in vitro fertilization assisted reproductive therapy time-lapse image recording image analysis software
hope from the cerebellum: tms-induced cognitive recovery after stroke

Conditions: Post-stroke Cognitive Impairment; Ischemic Stroke

Summary: the objective of this clinical trial is to investigate the effectiveness and safety of repetitive transcranial magnetic stimulation (rtms) in the cerebellum for individuals with post-stroke cognitive impairment. participants will undergo rtms in the cerebellar hemisphere opposite the lesion site, once daily for a total of five days.

the primary objective of this clinical trial is to investigate the effectiveness and safety of intermittent theta burst stimulation ( itbs) in the cerebellum for individuals with post-stroke cognitive impairment. the trial aims to answer two main questions: (1) what is the effectiveness of itbs in improving post-stroke cognitive impairment? (2) is itbs in the cerebellum safe for individuals with post-stroke cognitive impairment? participants will undergo itbs in the cerebellar opposite the lesion site, twice daily for five days. the control group will receive sham rtms with the same parameters and positions.

Eligibility criteria:
key inclusion criteria: (1)ischemic stroke, with an initial incident occurring within 2 weeks;(2)moca\<26; key exclusion criteria: (1)cerebral hemorrhage or subarachnoid hemorrhage;(2)a pre-existing history of epilepsy;

Keywords: post-stroke cognitive impairment repetitive transcranial magnetic stimulation high-frequency cerebellar
pharmacokinetics of favipiravir in volunteers with hepatic impairment

Conditions: Healthy; Hepatic Impairment

Summary: this study is designed to determine the pharmacokinetics of favipiravir in volunteers with hepatic impairment and in healthy control volunteers.


Eligibility criteria:
inclusion criteria: * hepatically impaired groups: * agree to doctor approved birth control methods from day 1 until 3 months following the final dose of study drug. * have mild hepatic impairment (child-pugh clinical assessment score grade a, score 5 6) or moderate hepatic impairment (child-pugh clinical assessment score grade b, score 7-9) or severe hepatic impairment (child-pugh clinical assessment score grade c, score 10-15); * control group * agree to doctor approved birth control methods from day 1 until 3 months following the final dose of study drug. * healthy as determined by medical history, physical exam, vital signs, ecgs, and clinical laboratory tests. exclusion criteria: * hepatically impaired groups: * have used any drugs known to significantly affect hepatic metabolism within 28 days, or is unable or unwilling to forgo the use of such products throughout the study; * have any acute or unstable condition or disease, other than impaired hepatic function, as determined by medical history, physical exam, ecg and clinical laboratory tests; * known ongoing alcohol and/or drug abuse within 1 month * any evidence of progressive worsening liver function disease as indicated by laboratory values; * have had an acute flare of hepatitis a or b within 6 months; * have acute, fulminant alcoholic hepatitis, determined either clinically or by histology; * have a history of hepatoma or metastatic disease of the liver; * control group: * have used any drugs known to significantly affect hepatic metabolism within 28 days, or is unable or unwilling to forgo the use of such products throughout the study; * have a history or presence of clinically cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, psychiatric, pulmonary, or renal disease or any other condition.

Keywords: healthy hepatic impairment t-705a favipiravir
latency antibiotics for previable rupture of membranes trial

Conditions: Preterm Prelabor Rupture of Membranes (PPROM)

Summary: the purpose of this study is to see if the use of prophylactic antibiotics in the expectant management of pprom less than 22 weeks significantly reduce the rate of delivery within 7 days and to see if the use of prophylactic antibiotics in the expectant management of pprom between 20 and 22 weeks decrease composite neonatal morbidity.


Eligibility criteria:
inclusion criteria: * preterm premature rupture of membranes at less than 22 weeks. * membrane rupture had occurred within 36 hours of randomization. * cervical dilatation is 3 cm or less (on visual or clinical examination). * 4 or fewer contractions in the 60-minute monitoring period before randomization. * singleton gestation. twin gestation reduced to singleton, either spontaneously or therapeutically, is not eligible unless the reduction occurred before 14 weeks project gestational age * gestational age at randomization less than 22 weeks (≤21 weeks and 6 days) based on clinical information. exclusion criteria: * nonreasoning fetal testing * vaginal bleeding * maternal or fetal indication for immediate delivery * cervical cerclage in place * receipt of latency antibiotics prior to randomization (azithromycin, ampicillin, or amoxicillin) * allergy to penicillins or azithromycin * febrile illness requiring antibiotics * placenta previa * multifetal gestation

Keywords: prophylactic antibiotics neonatal morbidity
extracellular volume associated with new-onset atrial fibrillation

Conditions: Cardiac Magnetic Resonance; Extracellular Volume Overload; Myocardial Infarction; Atrial Fibrillation

Summary: left ventricular fibrosis is strongly associated with atrial fibrillation (af). however, the relationship between lv fibrosis and new-onset af (noaf) after st-segment elevation myocardial infarction (stemi) is currently unknown. this study was to investigate the relationship between different regions of ecv and noaf during the acute phase of stemi. ecv in integral (integral ecv), non-myocardial infarction region (nmi-ecv) and myocardial infarction region (mi-ecv) was obtained by cmr.

this retrospective study included patients diagnosed with stemi at the affiliated hospital of xuzhou medical university. all patients underwent cmr during hospitalization, which included t1 mapping sequences. the blood sampling was collected within 24 hours of the cmr examination. inclusion criteria: 1. successful ppci (timi flow ≥ 2) within 12 hours after symptom onset; 2. admission to the cardiac care unit for continuous electrocardiogram (ecg) monitoring after ppci. exclusion criteria: 1. poor image quality; 2. history of myocardial infarction; 3. history of atrial fibrillation; 4. malignancy, or inflammatory disease; 5. severe valvular heart disease; 6. thyroid dysfunction. noaf was defined as post-admission atrial fibrillation without a history of atrial fibrillation. ecg monitoring revealed a suspicious rhythm during admission, and an immediate 12-lead ecg confirmed noaf. infarct-related arteries (ira) were recorded based on cag findings. ecv in integral (integral ecv), non-myocardial infarction region (nmi-ecv) and myocardial infarction region (mi-ecv) was obtained by cmr.

Eligibility criteria:
inclusion criteria: * successful ppci (timi flow ≥ 2) within 12 hours after symptom onset * admission to the cardiac care unit for continuous electrocardiogram (ecg) monitoring after ppci exclusion criteria: * poor image quality * history of myocardial infarction * history of atrial fibrillation * malignancy, or inflammatory disease * severe valvular heart disease * thyroid dysfunction
the role and mechanism of o-glcnac glycosylation modified has2 in the hyaluronic acid synthesis in ards

Conditions: Hyaluronic Acid

Summary: maintaining the normal function of the pulmonary microvascular barrier is critical for ards treatment. to assess the relationship between the has2 protein level, ha content and the clinical prognosis of ards in patients with ards. compare the has2 protein levels, hmw-ha and lmw-ha levels, endothelial injury indicators, and lungs in the blood of severe and non-ards severe patients and healthy adults admitted to the icu. the correlation between permeability, disease severity and prognosis to explore the predictability of has2-ha on the clinical outcome of ards.


Eligibility criteria:
inclusion criteria: 1.85 years≥age≥18 years. 2.moderate-to-severe ards, defined by the ards definition task force in the berlin definition (partial pressure of arterial oxygen \[pao2\]:fio2 ratio ≤200 mmhg with a peep ≥5 cmh2o). 3.diagnosis of ards less than 72 hours. exclusion criteria: all patients who meet any of the following criteria will be excluded at enrollment and randomization. 1. severe chronic respiratory diseases requiring long-term home oxygen therapy or noninvasive mv. 2. undrained pneumothorax or subcutaneous emphysema. 3. severe neuromuscular disease. 4. hemodynamic instability (\>30% increase in vasopressors within 6 hours or norepinephrine \>0.5 ug/kg/min) (am j respir crit care med. 2020; 201(2):178-187) . 5. contraindications to hypercapnia, such as intracranial hypertension or acute coronary syndrome. 6. severe other organs dysfunction with a low expected survival (7 days) or palliative care. 7. solid organ or hematologic tumors with the expected survival time less than 30 days. 8. participating in other clinical trials within 30 days. 9. pregnancy. 10. refusal to sign the informed consent.

Keywords: acute respiratory distress syndrome pulmonary microvascular endothelial barrier; hyaluronic acid hyaluronic acid synthase 2
effect of cyp2c9/cyp2c19 polymorphism on pharmacokinetics of phenobarbital in korean neonatal seizure patients.

Conditions: Neonatal Seizure

Summary: the pharmacogenomic profiles of drug metabolizing enzymes play an important role in pharmacokinetics (pk) of drugs. phenobarbital (pb), worldwidely used for neonatal seizure, is a drug that requires careful dose adjustments based on therapeutic drug monitoring. it was reported that phenobarbital (pb) metabolism was affected by cyp2c9 and cyp2c19 polymorphisms in adults. this study aims to evaluate the effects of the cyp2c9 and cyp2c19 genetic polymorphisms on pb pk in infants with neonatal seizure for an optimal dosing strategy.


Eligibility criteria:
inclusion criteria: * infant treated by phenobarbital monotherapy, diagnosed neonatal seizure * infant taken the drug concentration one more time * given the informed consent exclusion criteria: * progressed cns disorder * severe systemic illness * got/gpt level more than 2times of normal value,more than 3times elevation of bun/creatinine level * congenital hemolytic anemia * genetic disorder
study on safety and efficacy of an oral contraceptive in treating acne papulopustulosa

Conditions: Acne Vulgaris

Summary: the purpose of the study is to determine safety and efficacy of an oral contraceptive in treating acne papulopustulosa.

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany.bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * patients with mild to moderate facial papulopustular acne exclusion criteria: * contraindication against use of hormonal contraceptives

Keywords: acne papulopustulosa
effectiveness of a microbiome-directed food to promote programmatic and sustained nutritional recovery among children with uncomplicated acute malnutrition

Conditions: Malnutrition, Child

Summary: this study is an individually randomized controlled trial comparing microbiome-directed foods to standard nutritional therapy among children aged 6 to \< 24 months with uncomplicated acute malnutrition in terms of programmatic recovery by 12 weeks from admission and sustained recovery at 24 weeks from admission.


Eligibility criteria:
inclusion criteria: * for children with severe acute malnutrition (sam): muac \< 115 mm and/or wlz \< -3 and/or mild (+) or moderate (++) edema * for children with moderate acute malnutrition (mam): 115 mm ≤ muac \< 125 mm and/or -3 ≤ whz \< -2 * caregiver providing informed consent exclusion criteria: * medical complications requiring inpatient treatment, as identified by the national protocol * not eating/lack of appetite (as informed by appetite test and investigator judgement) * re-admission into the program within 2 months of previous default * for children with severe acute malnutrition (sam): referral from inpatient care (therapeutic feeding center, tfc) or supplementary feeding program (sfp) * for children with moderate acute malnutrition (mam): referral from sam treatment (tfc or otp) * presence of congenital abnormality or underlying chronic disease that may affect growth or risk of infection * known contraindication/ hypersensitivity/allergy to study interventions (chickpea/soy flour, banana, peanut) * residence outside the study catchment area or in a non-fixed (e.g. nomadic) community

Keywords: malnutrition sam mam child mdf microbiome
impact of listening to music on anxiety postoperative in a postanesthesic care unit (pacu) after spinal anesthesia

Conditions: Spinal Anesthesia

Summary: our hypothesis is that listening to music has a beneficial effect on the french population receiving spinal anesthesia for a scheduled procedure. we think we can reduce anxiety when switching to sspi, using creative music therapy software (music care) french validated by clinical research.

we want to demonstrate that listening to music: * decreases the anxiety of patients in phc; * improves their overall satisfaction unlike patients subjected to ambient noise from the sspi. demonstrate that there is a link between trait anxiety assessed preoperatively and state anxiety assessed immediate postoperative period to anticipate and improve patient care as soon as they arrive in sspi. extend music listening to all patients staying in a postoperative sspi or for procedures performed in sspi (bladder probing, central venous approach, post locoregional analgesia operative...) the music care software that we have chosen to use has been specifically developed to use the music as a therapeutic aid. numerous abstracts and clinical studies have been published on the subject the use of this software in reducing anxiety, pain, behavioral and changes in hemodynamic parameters. it is based on the use of the so-called "u" method, which is a relaxation method based on hypno-analgesia, thus offering a complete relaxation session to patient.

Eligibility criteria:
inclusion criteria : * adult patients; * undergoing scheduled orthopedic surgery, under spinal anesthesia; * non-cancerous, functional; * in traditional or outpatient hospitalization; * requiring a passage in pacu; * agreeing to participate in the study (consent form). exclusion criteria : * children; * under tutorship or curatorship; * having known hearing problems (hearing loss or not, deafness) reported during the anesthesia consultation or detected during the collection of preoperative data; having cognitive disorders (dementia, disorientation) reported during the consultation of anesthesia, not allowing questions to be answered * patients equipped with their personal music. the following will be excluded when they arrive in sspi: * patients who received a benzodiazepine during the intraoperative period; * patients whose spinal anesthesia has been converted to general anesthesia;

Keywords: pacu pain care music anxiety